Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT06409910RecruitingPhase 2
Comparing shorter radiation treatments for prostate cancer
This study tests two slightly different short-course radiation schedules for men who have had their prostate removed and are now getting follow-up radiation. The goal is to see if one is more effective or has fewer side effects.
London, OntarioAges 18 years+ - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT06362577Recruiting
HIFU vs Robot Surgery for Localized Prostate Cancer
This trial compares two treatments for localized prostate cancer: high-intensity focused ultrasound (HIFU) using a device called Sonablate and robot-assisted surgery. It aims to see which works better and has fewer side effects.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05613738Recruiting
Test drug for advanced prostate cancer with high PSMA scans
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
Beijing, Beijing MunicipalityAges 18–80 - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+ - NCT07156903Recruiting
Understanding patient and caregiver needs during prostate cancer radiation
This study asks people with prostate cancer and their caregivers about their needs during and after radiation treatment. It uses interviews to learn how to better support patients and families.
BerlinAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
San Diego, CaliforniaAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT06408298RecruitingEarly Phase 1
Hydroxychloroquine before prostate cancer surgery
This trial tests whether a drug called hydroxychloroquine (HCQ) can help before prostate cancer surgery. It is for people with localized prostate cancer who are planning to have their prostate removed.
Lebanon, New HampshireAges 18 years+ - NCT06044025RecruitingPhase 1
Maintenance therapy for prostate cancer with rising PSA
This trial tests two medications (metformin and a turmeric compound) as a maintenance therapy for men with prostate cancer whose PSA is rising slowly after prior treatment. The goal is to see if these drugs can keep the cancer from growing while you take a break from standard hormone therapy.
Little Rock, ArkansasAges 18–100 - NCT07492927Recruiting
Liquid biopsy for prostate cancer diagnosis
This study uses a blood test to detect prostate cancer more accurately than traditional methods. It looks for genetic material from cancer cells to help decide if a prostate biopsy is needed.
Chicago, IllinoisAges 18 years+ - NCT06661122Recruiting
Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Multiple LocationsAges 18 years+ - NCT07130682Recruiting
Proton therapy in two sessions for prostate cancer
This trial tests if giving proton radiation in just two sessions, guided by MRI, is safe and effective for low- or intermediate-risk prostate cancer. It may mean fewer trips to the hospital for treatment.
Hong KongAges Any age - NCT07693075RecruitingPhase 2
Radiotherapy for high-risk prostate cancer with boost to tumor
This trial tests a special type of radiation therapy that gives a higher dose to the tumor while treating the whole prostate. It is for men with high-risk or very high-risk prostate cancer that has not spread to distant organs.
CairoAges 18 years+ - NCT06927635RecruitingPhase 2
SBRT vs standard care for prostate cancer that has spread to a few spots
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Toronto, OntarioAges 18–100 - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT06585007RecruitingPhase 3
Radiation for limited cancer growth in castration-resistant prostate cancer
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
LeuvenAges 18 years+ - NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT07357259Recruiting
Delayed pelvic scan with PSMA PET/CT for high-risk prostate cancer
This trial uses a special PET/CT scan with a radioactive tracer (PSMA) to get detailed images of the pelvis in men with high-risk prostate cancer. The goal is to improve cancer staging and detect recurrence more accurately.
Bologna, ItalyAges 30 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,366 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.